Global Survey Suggests Consumers Overestimate their Ability to Detect Deepfakes
New global research from Jumio reveals disconnect between consumer awareness of generative AI and deepfakes…
News
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Comerica Incorporated (CMA) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Santhera Publishes Annual Report 2022
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals…
Santhera Publishes Annual Report 2022
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals…
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
BioSyent Announces Approval of New Product
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
BioSyent Announces Approval of New Product
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Telesis Bio Secures Financing of $28.0 Million
Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC…
Telesis Bio Secures Financing of $28.0 Million
Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC…
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a…
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a…
Cronos Group Announces Streamlined Operating Structure to Improve Cash Flow
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in…
Cronos Group Announces Streamlined Operating Structure to Improve Cash Flow
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in…
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients…
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients…